Impact of DMARD class on vaccine response in the IMID and control groups
| csDMARD | bDMARD | tsDMARD | Controls | |
| Continue group | ||||
| Detectable SARS-CoV2 IgG Abs* | ||||
| Post first vaccine dose (p=0.000) | 9/22 (40.91) | 25/32 (78.13) | 5/26 (19.23) | 46/51 (90.20) |
| P=0.000 | P=0.116 | P=0.000 | ||
| Post second vaccine dose (p=0.748) | 28/30 (93.33) | 30/34 (88.24) | 23/26 (88.46) | 49/49 (100) |
| P=0.141 | P=0.025 | P=0.039 | ||
| Mean SARS-CoV2 IgG Ab titre† | ||||
| Post first vaccine dose (p=0.000) | 2.40 (4.90) | 5.96 (7.56) | 1.24 (2.5) | 8.91 (11.77) |
| 0.5 (1.9) | 3.3 (7.2) | 0.5 (0.75) | 4.2 (8.4) | |
| P=0.000 | P=0.232 | P=0.000 | ||
| Post second vaccine dose (p=0.009) | 62.11 (80.90) | 59.19 (67.47) | 12.88 (18.23) | 79.49 (136.74) |
| 22.95 (77.9) | 41.95 (80.1) | 4.9 (20.2) | 48.4 (67.2) | |
| P=0.490 | P=0.551 | P=0.000 | ||
| Withhold group | ||||
| Detectable SARS-CoV2 IgG Ab* | ||||
| Post first vaccine dose (p=0.070) | 16/20 (76.19) | 22/24 (91.67) | 18/28 (64.3) | 46/51 (90.20) |
| P=0.143 | P=0.603 | P=0.007 | ||
| Post second vaccine dose | 20/20 (100) | 20/20 (100) | 27/27 (100) | 49/49 (100) |
| Mean SARS-CoV2 IgG Ab titre† | ||||
| Post first vaccine dose (p=0.110) | 6.05 (12.31) | 4.85 (3.98) | 3.4 (4.66) | 8.91 (11.77) |
| 2.85 (3.9) | 3.7 (6.5) | 1.4 (2.75) | 4.2 (8.4) | |
| P=0.076 | P=0.431 | P=0.002 | ||
| Post second vaccine dose (p=0.617) | 70.57 (107.13) | 74.05 (71.60) | 86.27 (150.6) | 79.49 (136.74) |
| 43.45 (96.4) | 64.65 (74) | 40.65 (91.9) | 48.4 (67.2) | |
| P=0.642 | P=0.319 | P=0.831 |
Data are presented as proportions (%) or mean (SD) and median (IQR).
Comparison of DMARD categories with controls using Fisher’s exact test or Wilcoxon-Mann-Whitney U test as appropriate with significance cut-off 5%.
*Using Fisher’s exact test with significance cut-off 5%.
†Using Kruskal-Wallis test among the immunosuppression groups only with significance cut-off 5%.
Ab, antibody; bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; IMID, immune-mediated inflammatory disease; tsDMARD, targeted synthetic DMARD.